Frank Comunas
Internal Medicine · Albuquerque, NMNPI 1295829661
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 73 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 17.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $533 and has fallen 65.6% since, to $183 in 2025.
Across 73 payments — averaging $18.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$230
- Abiomed$190
- Novo Nordisk$156
- Amgen$155
- GSK$90
- Lilly USA, LLC$77
- plus $427 from 13 others
What the payments were for
- Food & beverage$1,326100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 14 | $230 |
| Abiomed | 4 | $190 |
| Novo Nordisk | 12 | $156 |
| Amgen | 8 | $155 |
| GSK | 6 | $90 |
| Lilly USA, LLC | 4 | $77 |
| Astellas Pharma US Inc | 4 | $69 |
| Otsuka America Pharmaceutical, Inc. | 3 | $60 |
| Pfizer | 3 | $53 |
| Johnson & Johnson | 2 | $41 |
| Novartis | 2 | $34 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $31 |
| Exact Sciences | 2 | $30 |
| Boehringer Ingelheim | 2 | $29 |
| SK Life Science, Inc. | 1 | $20 |
| Bayer | 1 | $17 |
| Abbott | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $13 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$110
How this compares
$1,326 in reported general payments places this provider in the 85th percentile of 578 internal medicine providers in New Mexico.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 40 | $37,244 |
| EliquisApixaban | 29 | $27,006 |
| JanuviaSitagliptin Phosphate | 15 | $20,485 |
| Spiriva RespimatTiotropium Bromide | 17 | $16,898 |
| FarxigaDapagliflozin Propanediol | 11 | $16,804 |
| Arnuity ElliptaFluticasone Furoate | 32 | $7,919 |
| Atorvastatin Calcium | 317 | $5,403 |
| SymbicortBudesonide/Formoterol Fumarate | 16 | $4,192 |
| Levothyroxine Sodium | 267 | $4,105 |
| Lisinopril | 264 | $3,547 |
| Tamsulosin Hcl | 137 | $3,044 |
| Gabapentin | 209 | $2,987 |
| Losartan Potassium | 168 | $2,810 |
| AsmanexMometasone Furoate | 11 | $2,093 |
| Metoprolol Succinate | 116 | $1,949 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $41 | $37,24440 claims |
| PfizerEliquis | $53 | $27,00629 claims |
| MerckJanuvia, Asmanex | $13 | $22,57726 claims |
| AstraZenecaFarxiga, Symbicort | $230 | $20,99727 claims |
| Boehringer IngelheimSpiriva Respimat | $29 | $16,89817 claims |
| GSKArnuity Ellipta | $90 | $7,91932 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 578 internal medicine providers in New Mexico.
Other internal medicine in Albuquerque
- Edward LewieckiAlbuquerque$491K
- James AdairAlbuquerque$108K
- Gulshan ParasherAlbuquerque$66K
- Mark WalkerAlbuquerque$24K
- Joao TeixeiraAlbuquerque$18K
- Karla AlmarazAlbuquerque$18K
- David SosaAlbuquerque$11K
- Revati ReddyAlbuquerque$7K
- Ross DavidsonAlbuquerque$7K
- Edmee RodriguezAlbuquerque$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.